The 36-month beta value for PGEN is also noteworthy at 1.85. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for PGEN is 146.38M, and at present, short sellers hold a 18.64% of that float. The average trading volume of PGEN on July 09, 2025 was 1.67M shares.
PGEN) stock’s latest price update
The stock price of Precigen Inc (NASDAQ: PGEN) has jumped by 14.41% compared to previous close of $1.7. Despite this, the company has seen a gain of 34.14% in its stock price over the last five trading days. seekingalpha.com reported 2025-07-07 that Precigen’s future hinges on the FDA’s approval of PRGN-2012, with a pivotal decision expected August 27, 2025. PRGN-2012 shows strong efficacy and safety, potentially transforming the treatment of Recurrent Respiratory Papillomatosis and opening up a $2 billion global market opportunity. Despite promising science, Precigen has long-faced severe financial challenges and a very short cash runway into 2026.
PGEN’s Market Performance
PGEN’s stock has risen by 34.14% in the past week, with a monthly rise of 29.67% and a quarterly rise of 46.24%. The volatility ratio for the week is 7.83% while the volatility levels for the last 30 days are 7.28% for Precigen Inc The simple moving average for the last 20 days is 27.27% for PGEN’s stock, with a simple moving average of 52.69% for the last 200 days.
Analysts’ Opinion of PGEN
Cantor Fitzgerald gave a rating of “Overweight” to PGEN, setting the target price at $7 in the report published on November 18th of the previous year.
PGEN Trading at 33.71% from the 50-Day Moving Average
After a stumble in the market that brought PGEN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -10.37% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PGEN starting from Perez Jeffrey Thomas, who purchase 58,823 shares at the price of $0.85 back on Aug 09 ’24. After this action, Perez Jeffrey Thomas now owns 743,097 shares of Precigen Inc, valued at $50,000 using the latest closing price.
KIRK RANDAL J, the Director of Precigen Inc, purchase 23,529,411 shares at $0.85 during a trade that took place back on Aug 09 ’24, which means that KIRK RANDAL J is holding 64,547,214 shares at $19,999,999 based on the most recent closing price.
Stock Fundamentals for PGEN
Current profitability levels for the company are sitting at:
- -31.71 for the present operating margin
- -0.02 for the gross margin
The net margin for Precigen Inc stands at -37.29. The total capital return value is set at -1.27. Equity return is now at value -278.55, with -118.84 for asset returns.
Based on Precigen Inc (PGEN), the company’s capital structure generated -0.63 points at debt to capital in total, while cash flow to debt ratio is standing at -13.0. The debt to equity ratio resting at -0.39. The interest coverage ratio of the stock is -26643.0.
Currently, EBITDA for the company is -123.5 million with net debt to EBITDA at 0.0. When we switch over and look at the enterprise to sales, we see a ratio of 137.92. The receivables turnover for the company is 3.95for trailing twelve months and the total asset turnover is 0.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.53.
Conclusion
In summary, Precigen Inc (PGEN) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
